TAMPA, Fla.--(BUSINESS WIRE)--May 24, 2006--Accentia BioPharmaceuticals, Inc. (NASDAQ: ABPI - News) and its majority-owned subsidiary, Biovest International, Inc. (OTCBB: BVTI - News), will present long-term follow-up data from the Company's Phase 2 trial of BiovaxID(TM) at the annual meeting of the American Society of Clinical Oncologists (ASCO). The meeting is the annual educational and scientific event of this professional organization representing physicians who treat cancer patients. This year's meeting will be held June 2 through June 6, 2006, at the Georgia World Congress Center in Atlanta.
